![Jacob J. Clement](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Jacob J. Clement
Former positions of Jacob J. Clement
Companies | Position | Start | End |
---|---|---|---|
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 31/01/2009 | 31/01/2009 |
Training of Jacob J. Clement
The University of North Carolina at Charlotte | Doctorate Degree |
Roosevelt University | Graduate Degree |
Saint Mary's University | Undergraduate Degree |
Statistics
International
United States | 3 |
Canada | 3 |
Operational
Graduate Degree | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Consumer Services | 4 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Jacob J. Clement
- Experience